Razadyne/Reminyl (Alzheimers Disease) - Forecast and Market Analysis to 2022
Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022
Summary- GlobalData has released its new PharmaPoint Drug Evaluation report, "Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
Razadyne (also known as Reminyl) is a reversible, competitive AChEI indicated for the treatment of mild to moderate AD. The exact MOA of galantamine is not known; however, it is thought to exert its effects by enhancing cholinergic function as a result of an increase in the concentration of ACh through reversible inhibition of hydrolysis by cholinesterase.
Scope- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Razadyne / Reminyl including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Razadyne / Reminyl for the top eight countries from 2012 to 2022. - Sales information covered for France, Germany, Italy, Spain, the UK, Japan, China and India.
Reasons to buy- Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for AD - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Razadyne / Reminyl performance - Obtain sales forecast for Razadyne / Reminyl from 2012-2022 in top eight countries (France, Germany, Italy, Spain, the UK, Japan, China and India)
Table of Contents- 1 Table of Contents 51.1 List of Tables 71.2 List of Figures 72 Introduction 82.1 Catalyst 82.2 Related Reports 93 Disease Overview 113.1 Etiology and Pathophysiology 123.1.1 Etiology 12
3.1.2 Pathophysiology 153.2 Symptoms 274 Disease Management 294.1 Diagnosis 294.1.1 Probable Alzheimer's Disease Dementia 304.1.2 Possible AD Dementia 314.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 314.1.4 Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process 324.1.5 Preclinical AD 324.1.6 Mild Cognitive Impairment 334.2 Treatment Overview 355 Competitive Assessment 385.1 Overview 385.2 Strategic Competitor Assessment 386 Razadyne/ Reminyl 416.1 Overview 416.2 Efficacy 426.3 Safety 446.4 SWOT Analysis 446.5 Forecast 45
7 Appendix 467.1 Bibliography 467.2 Abbreviations 517.3 Methodology 547.4 Forecasting Methodology 547.4.1 Diagnosed AD patients 557.4.2 Percent Drug-treated Patients 567.4.3 General Pricing Assumptions 567.4.4 Individual Drug Assumptions 587.4.5 Generic Erosion 587.5 Physicians and Specialists Included in this Study 597.6 About the Authors 607.6.1 Author 607.6.2 Global Head of Healthcare 617.7 About GlobalData 627.8 Disclaimer 62
List of Tables- Table 1: Symptoms of AD 28Table 2: Guidelines for the Treatment of AD 35Table 3: Most Prescribed Drugs for AD by Class in the Global Markets, 2012 36Table 4: Leading Branded Treatments for AD, 2013 39Table 5: Product Profile Razadyne 42Table 6: Razadyne SWOT Analysis, 2013 44Table 7: Global Sales Forecasts ($m) for Razadyne, 20122022 45
List of Figures- Figure 1: Atrophy of the Brain in AD 17Figure 2: Key Pathological Features in AD Versus a Healthy Neuron 19Figure 3: Non-Amyloidogenic Metabolism of APP 21Figure 4: Amyloidogenic Metabolism of APP 22Figure 5: Neurofibrillary Tangles 24Figure 6: Oxidative Damage Due to Free Radicals 26Figure 7: Strategic Competitor Assessment of the Marketed Products in AD, 2013 40
Read the full report: Razadyne/Reminyl (Alzheimer's Disease) - Forecast and Market Analysis to 2022
For more information:Sarah Smith
Research Advisor at Reportbuyer.com
Email: Tel: +44 208 816 85 48